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Background: Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise
guidelines.
Patients and methods: The clinico-pathological features of 38 HIV-negative patients with IVL
were reviewed to define efficacy of chemotherapy in these malignancies. Clinical characteristics of
22 patients treated with chemotherapy and of 16 untreated patients were compared in order to under-
stand better the impact and causes of potential patient selection.
Results: Median age was 70 years (range 34–90), with a male/female ratio of 0.9; 23 (61%) patients
had Eastern Cooperative Oncology Group performance status (ECOG-PS) >1; 21 (55%) had systemic
symptoms. Cutaneous lesions and anemia were significantly more common among patients treated
with chemotherapy; central nervous system (CNS) and renal involvement were significantly more
common among untreated patients. Chemotherapy was associated with a response rate of 59% and a
3-year overall survival of 33 +_ 11%. Five of six patients with CNS involvement received
chemotherapy: four of them died early; only one patient, treated with adriamycin, cyclophosphamide,
vincristine, methotrexate, bleomycin and prednisolone (MACOP-B) followed by high-dose
chemotherapy and autologous stem cell transplantation (ASCT), was alive at 19 months. High-dose
chemotherapy supported by ASCT was indicated at diagnosis in another patient (43 years of age,
stage I), who was alive at 71 months, and at relapse after cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP) in two patients who died early after transplantation. PS <_1, disease limited to
the skin, stage I, and use of chemotherapy were independently associated with better outcome.
Conclusions: Anthracycline-based chemotherapy is the standard treatment for IVL. However, survi-
val is disappointing, with a relevant impact of diagnostic delay and lethal complications. More inten-
sive combinations, containing drugs with higher CNS bioavailability, are needed in cases with brain
involvement, and the role of high-dose chemotherapy supported by ASCT should be further investi-
gated in younger patients with unfavorable features.
Key words: angiotropic lymphoma, chemotherapy, CHOP regimen, CNS lymphoma, cutaneous
lymphoma, intravascular lymphomatosis
Introduction
Correct therapeutic assessment is very difficult in rare
malignancies, not only because of the intrinsic difficulty of
performing prospective trials, but also because the reported
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data are often fragmented and potentially biased. Angiotropic
or intravascular lymphoma (IVL) is a classic example of these
considerations since the relevant literature is almost exclusively
made up of case reports, cumulative reviews and occasional
case series that do not exceed 10–15 patients [1–3].
IVL is considered to be a rapidly aggressive and usually dis-
seminated disease, characterized by exclusive or predominant
growth of neoplastic cells within blood vessel lumina [4, 5].
IVL usually affects elderly patients, and is associated with
poor performance status (PS), B symptoms, anemia, an elev-
ated erythrocyte sedimentation rate (ESR) and elevated serum
lactate dehydrogenase (LDH) levels. The brain and skin are the
most frequently involved organs, while lymph nodes are
usually spared. The optimal therapeutic strategy has not been
identified. The heterogeneity of clinical symptoms and the lack
of diagnostic algorithms may be responsible for a delayed
diagnosis in many cases of IVL, hindering the timely delivery
of treatment. Moreover, as IVL patients are usually aged and
display poor PS, the use of intensive treatment per se may be
troublesome. The published data suggest anthracycline-based
chemotherapy as the best therapeutic choice considering the
aggressive and disseminated nature of IVL. However, reported
results with this strategy are conflicting, and the apparent clini-
cal benefit may reflect selection bias rather than therapeutic
efficacy. The analysis of a large, multicenter retrospective
series is a useful strategy in order to clarify this issue.
This paper reports therapeutic management and outcome in
the largest reported series of patients with IVL treated with
anthracycline-based chemotherapy. An analysis of potential
selection bias in the interpretation of therapeutic efficacy, by




Twenty-two centers affiliated with the International Extranodal Lym-
phoma Study Group (IELSG) provided demographic, clinical, pathologi-
cal, therapeutic and survival data of HIV-negative patients with an in vivo
or post-mortem pathological diagnosis of IVL. Clinical and laboratory
characteristics considered for analysis were assessed around the time of
pathological diagnosis. Histopathological categorization was performed
according to the World Health Organization (WHO) classification criteria
[6]. The study group consisted of 38 patients diagnosed from 1985 to
2003. Diagnosis was established in vivo in 30 patients and at autopsy in
eight cases. Staging work-up included physical examination, com-
plete biochemical profile, whole-body computed tomography (CT) scan-
ning, and bone marrow aspirate and biopsy. Stage of disease was defined
according to the Ann Arbor staging system. Some procedures, such as CT
or magnetic resonance imaging (MRI) of the brain, CSF cytology examin-
ation, gastroscopy, abdominal ultrasound or hysteroscopy were indicated
according to the presenting symptoms.
Therapeutic management
Twenty-two patients were treated with chemotherapy which was anthracy-
cline-based in 19 cases; 16 patients did not receive chemotherapy (eight
with in vivo diagnosis and eight autoptic cases). A comparison of
the clinical characteristics between these two subgroups is reported in
Table 1. Therapeutic management is summarized in Table 2.
Statistical considerations
Distribution of variables between patients who either received or did not
receive chemotherapy was investigated using the Fisher’s exact test
for categorical variables. Survival curves were generated by the
Kaplan–Meier method. Overall survival (OS) was calculated from the
date of pathological diagnosis to death or to the last date of follow up,
while event-free survival (EFS) was calculated from the first day of treat-
ment to relapse, progression or death, or to the last date of follow-up.
The association of survival with clinical and therapeutic variables was
evaluated using the log-rank test. The independent prognostic value of
variables was analyzed using the Cox model. Backward stepwise
regression was performed to identify the most powerful predictors of sur-
vival. All the probability values were two-sided, with values of P < 0.05
considered significant. Analyses were carried out using the statistical
package Statistica 4.0 for Windows (Statsoft; Tulsa, OK, USA).
Results
Patient characteristics
Thirty-eight patients had a median age of 70 years (range
34–90), with a male/female ratio of 0.9. Clinical presentation
was extremely heterogeneous, with a remarkable deterioration
in PS in many cases (>_1 in 36 cases; 95%). The median time
from onset of symptoms to histological diagnosis was 1.06
months (range 0.3–24.8) for patients treated with chemother-
apy, 3.78 months (range 0.2–25) for patients with in vivo diag-
nosis but treated without chemotherapy and 3.14 months (range
2–6) for cases diagnosed at autopsy (P = 0.0005). No signifi-
cant differences in age, gender, PS, stage of disease or fre-
quency of elevated serum LDH levels between patients treated
with chemotherapy and untreated patients were observed
(Table 1). Conversely, cutaneous lesions (55% versus 19%;
P = 0.04) and anemia (77% versus 44%; P = 0.04) were more
common among patients treated with chemotherapy; whereas
CNS (23% versus 63%; P = 0.02), renal involvement (5% ver-
sus 31%; P = 0.05) and cardio-pulmonary infiltration (5% ver-
sus 31%; P = 0.05) were less common (Table 1). Ten patients
(seven in the group treated with chemotherapy and three in the
other group) had disease limited to the skin (‘cutaneous form’).
Twenty-one patients (55%) had systemic symptoms, mainly
fever, which were more common in patients treated with che-
motherapy (68% versus 38%; P = 0.09). Concomitant involve-
ment of liver, spleen and marrow was observed in eight patients
(21%). Overall, bone marrow biopsies were positive in 12
cases (32%). No difference in the frequency of involvement of
these organs between both studied subgroups was observed.
With the exception of anemia, no differences in laboratory
findings between patients treated with chemotherapy and
patients who did not receive systemic treatment were observed
(Table 1). Anemia was the most frequent cytopenia. Leuko-
penia or thrombocytopenia did not occur without anemia. Eight
of 11 (73%) patients with thrombocytopenia had concomitant
bone marrow infiltration and hepatosplenic involvement. Of all
the patients with marrow infiltration, one had anemia and eight
1216
Downloaded from https://academic.oup.com/annonc/article-abstract/15/8/1215/143872
by Università degli Studi di Milano user
on 25 July 2018
of them also had thrombocytopenia; nine of 13 patients with
hepatic and/or splenic involvement had anemia or thrombocy-
topenia. When analysis of the patients’ characteristics was lim-
ited to patients who did not receive chemotherapy, as expected,
the sole significant difference between patients with in vivo
diagnosis and autopsy cases was more disseminated disease in
the latter subgroup.
Patients treated with chemotherapy
Twenty-two patients were treated with primary chemotherapy
(anthracycline-based in 19 patients). Ten patients achieved
complete remission (CR) and three a partial response (PR),
with an overall response rate of 59%; seven patients experi-
enced progressive disease (PD) and two died of toxicity
(TD). Among the responders, seven subsequently experie-
nced relapse, which invariably involved extranodal organs
and, mostly, the primary site of disease.
Five of six patients with CNS involvement detected during
staging were treated with chemotherapy. Three of them recei-
ved CHOP chemotherapy and one was treated with the cyclo-
phosphamide, vincristine and prednisone (CVP) regimen, none
achieved CR, and all died within 4 months of diagnosis. The
fifth patient with CNS involvement and treated with che-
motherapy was a 52-year-old woman, with multiorgan disease
other than CNS involvement, who was treated with the
MACOP-B regimen followed by high-dose chemotherapy sup-
ported by autologous stem cell transplantation (ASCT). She is
alive and relapse-free at 19 months from diagnosis. Another
patient (43 years of age), with a single endometrial lesion,
was treated with the CHOP regimen followed by consolidative
high-dose chemotherapy supported by ASCT; she is alive and
relapse-free 71 months from diagnosis. Three patients treated
without anthracyclines (CVP regimen) experienced disease
progression within 9 months of diagnosis: two died a few
weeks after relapse, while the third experienced sponta-
neous regression of a cutaneous relapse, and is alive with no
evidence of disease 10 years from diagnosis. In the whole
cohort, all failures but one occurred within the first year of
follow up. The median time to treatment failure for 22 patients
treated with primary chemotherapy was 8 months (range
1–71), with a 3-year EFS of 27%.
Six of 14 patients who experienced PD or relapse received
salvage therapy: conventional chemotherapy in four cases (two
PD, two PR) and high-dose chemotherapy supported by ASCT
in two cases (TD, PD). The survival duration from relapse was
7, 8, 9 + and 19 months, and 2 and 18 months, respectively. All
but one patient who did not receive salvage therapy died within
4 weeks of relapse.
Eight patients treated with primary chemotherapy were alive
(seven disease-free) at a median follow up of 35 months
Table 1. Patients’ characteristics
Variable Chemotherapy
group, n (%) (n = 22)
No chemotherapy
group, n (%) (n = 16)
P
Age, years
Median (range) 69 (39–86) 71 (34–90) 0.82
Male sex 11 (50) 7 (44) 0.75
ECOG PS >_ 3 10 (45) 11 (69) 0.19
Other malignanciesa 2 (9) 4 (25) 0.21
Stage-I disease (Ann Arbor) 6 (27) 6 (38) 0.72
Systemic symptoms 15 (68) 6 (38) 0.09
Cutaneous lesions 12 (55) 3 (19) 0.04
CNS involvement 5 (23) 10 (63) 0.02
Hepatosplenic involvement 8 (36) 5 (38) 1.00
Bone marrow infiltration 8 (36) 4 (25) 0.50
Cardio-pulmonary involvement 1 (5) 5 (25) 0.05
Renal involvement 1 (5) 5 (31) 0.05
Anemia 17 (77) 7 (44) 0.04
Thrombocytopenia 8 (36) 3 (19) 0.29
Increased serum LDH levelb 18/20 (90) 7/9 (78) 0.56
Increased erythrocyte sedimentation rate 12 (55) 4 (25) 0.10
Hypoalbuminemia 5 (23) 1 (9) 0.36
aThe other malignancy was diagnosed prior to IVL in five cases (gastric MALT lymphoma, diffuse large
B-cell lymphoma of the parotid, prostate cancer, breast cancer, colon cancer) and concomitant to IVL in one
case (renal cancer).
bNumber of positive cases on assessed patients (20 treated with chemotherapy and nine untreated).
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(range 21–126), with a 3-year OS of 33% (figure 1). Among
the surviving patients, three had IVL limited to the skin at
diagnosis and two had stage I disease.
Patients who did not receive chemotherapy
In spite of an in vivo diagnosis of IVL, eight patients did not
receive chemotherapy. Three of them were young women
(<50 years of age) displaying IVL limited to the skin: two
(with single lesions) were treated with surgical resection or
radiotherapy and were alive and relapse-free at 7 and 14 years
from diagnosis; the third patient (multiple cutaneous lesions)
was treated with corticosteroids and was lost to follow up
after 1 month. A 78-year-old man was not treated due to con-
comitant renal cancer; he died from other causes while pro-
gression-free at 24 months from diagnosis. A 73-year-old man
experienced early CNS dissemination and died before the start
of any treatment. Three patients were referred to surgical
resection of uterine, renal and gallbladder masses with diag-
nostic purpose and did not receive cytotoxic treatment due to
fatal post-surgical complications: renal failure in two women
(74 and 90 years of age) and pulmonary thromboembolism in
a 63-year-old man. Overall, only three women with disease
limited to the skin survived without chemotherapy, with a
3-year OS of 29% for the subgroup of patients with in vivo
diagnosis who did not receive chemotherapy. No significant
difference between treated and untreated patients with in vivo
diagnosis was observed (Figure 1).
Predictors of survival
Multivariate analysis performed on the entire series and
adjusted for age (continuous variable), ECOG-PS (0–1
versus >_2), clinical presentation (disease limited to the skin or
‘cutaneous form’ versus others), stage (I versus IV), B symp-
toms (no versus yes), serum LDH level (normal versus
increased), anemia (no versus yes) and use of chemotherapy
(no versus yes) showed a significant and independent associ-
ation between the use of chemotherapy and survival {odds ratio
(OR), 0.24 [95% confidence interval (CI)] 0.09–0.59};
P = 0.005]. PS <1 [OR, 0.23 (95% CI 0.08–0.63); P = 0.008],
‘cutaneous form’ [OR, 0.28 (95% CI 0.08–0.91); P = 0.05] and
stage I disease [OR, 0.28 (95% CI 0.09–0.81); P = 0.02] were
also independently associated with a better OS. When a multi-
variate analysis limited to patients with in vivo diagnosis
was performed, the association between the use of chemo-
therapy and survival was approaching significance [OR, 0.18
(95% CI = 0.02–1.04); P = 0.06], while the predictive role of
the other three variables remained unchanged (data confirmed
by backward stepwise regression).
Discussion
The analysis of therapeutic strategies and outcome from the
present series of patients with IVL suggests that all patients
with IVL should be considered as having disseminated dis-
ease, and, accordingly, treated with combination chemother-
apy. A possible exception might be represented by cases with
single small cutaneous lesions, which have some probability
of cure with local treatment. The inclusion of anthracycline as
part of chemotherapy combinations appears critical because
the use of other regimens without these drugs has been associ-
ated with disappointing outcome [7, 8]. In our series, each of
the three patients treated with CVP regimen relapsed within
9 months, and two of them died within a few weeks of relapse.
Figure 1. Overall survival curves for 22 patients treated with
chemotherapy (continuous line) and the eight untreated patients with an
in vivo diagnosis (dotted line) (P = 0.31).
Table 2. Therapeutic management
Treatment No. of patients
Chemotherapy 22
Anthracycline-based 19
CHOP or CEOP regimena,b 16
CNOPb 2
MACOP-Ba 1






aTwo patients received high-dose chemotherapy supported by ASCT as
consolidation after primary chemotherapy.
bThree patients with CNS involvement were also treated with intrathecal
chemotherapy.
cEight patients for whom IVL diagnosis was performed only at autopsy
were included in this subgroup.
ASCT, autologous stem cell transplantation; CEOP, cyclophosphamide,
epirubicin, vincristine and prednisone; CHOP,
cyclophosphamide, doxorubicin, vincristine and prednisone; CNOP,
cyclophosphamide, mitoxantrone, vincristine and predinisone; CNS,
central nervous system; MACOP-B, adriamycin, cyclophosphamide,
vincristine, methotrexate, bleomycin and prednisolone; CVP,
cyclophosphamide, vincristine and prednisone.
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Conversely, anthracycline-based chemotherapy was associated
with a 59% response rate and a 3-year OS rate of 32 +_ 11%.
Several cases of objective response after CHOP or CHOP-
like chemotherapy have been previously reported [9–11];
however, follow-up in these case reports was short and, in
many other cases, this strategy has been followed by inexor-
able progression [12–15]. There were fewer than 50 patients
with IVL treated with anthracycline-based chemotherapy and
assessable for outcome reported in the literature (published in
English). Half of them relapsed and died within 18 months of
diagnosis and one third of relapses involved the CNS [14, 16].
In one third of cases, the follow up of survivors was >1 year;
nearly 10% of cases were alive and disease-free with a follow
up of >3 years [1, 9, 17, 18].
In spite of some encouraging anecdotal evidence [1, 17,
19], the vast majority of reported patients with CNS involve-
ment treated with anthracycline-based chemotherapy relapsed
and died within 9 months of chemotherapy [20, 21]. In our
series, five patients with CNS involvement were treated with a
CVP, CHOP or MACOP-B regimen. Despite initial responses,
three patients relapsed and died within 4 months of diagnosis
and one died of septic complications; only the patient treated
with MACOP-B followed by high-dose chemotherapy sup-
ported by ASCT is alive and disease-free at 19 months. Thus,
a more intensive combination is needed in cases with CNS
involvement, and consistent with previous reports [1, 22, 23],
drugs with higher bioavailability in the CNS, such as metho-
trexate or cytarabine, should be included.
The use of high-dose chemotherapy supported by ASCT, an
important strategy to intensify treatment against NHL, may
improve current outcomes. However, this strategy appears
feasible only in a small proportion of patients with IVL, con-
sidering that their median age is 70 years and PS is usually
poor. Worldwide experience with this treatment modality in
IVL is extremely limited, with some encouraging results both
as first- and second-line treatment [18, 24, 25]; however, it is
possible that some unsuccessfully treated IVL patients have
not been reported. In our series, four patients were treated
with high-dose chemotherapy supported by ASCT as consoli-
dation treatment after anthracycline-based chemotherapy
(CHOP and MACOP-B regimens) in two cases. They are both
alive and relapse-free at 19 and 71 months from diagnosis.
In the other two cases, this strategy was used as salvage
therapy for systemic relapses that occurred after CHOP che-
motherapy; no responses were observed, both patients died
early after transplantation. Thus, the role of early consolida-
tion with high-dose chemotherapy supported by ASCT appears
to be a promising approach and deserves to be investigated
further in young patients with unfavorable features.
Since IVL is usually a disseminated malignancy, the role of
radiation therapy appears of secondary importance. Notwith-
standing, radiotherapy may be considered the exclusive treat-
ment in elderly patients with single cutaneous lesions. Its use
as consolidation therapy after chemotherapy has been reported
in cases with CNS involvement [3, 26] or bulky extranodal
disease [9, 27], but its true efficacy cannot be determined
from these reports. Other therapeutic strategies have been
used anecdotally, including interferon [28], plasmapheresis
[3, 29] and a case of cutaneous IVL successfully treated with
rituximab [30].
The clinical benefit offered by chemotherapy could poten-
tially reflect a selection bias. In the present series, the com-
parison between patients treated with chemotherapy and
patients who did not receive this therapy might contribute to a
better understanding of the real reasons for patient selection
and its prognostic impact on this rare malignancy. First of all,
our data seem to suggest that patient selection is not due to
age, PS or disease extent. Well-known prognostic factors for
aggressive lymphomas, such as age, PS, stage of disease and
serum LDH level, displayed a similar distribution between the
studied subgroups. Actually, patient selection in our series
could be attributed to a higher rate of post-surgical compli-
cations, a different clinical presentation profile and the lack of
diagnostic suspicion of IVL. In fact, only two patients experi-
enced fatal complications in the group of patients treated with
chemotherapy, while, in the other group, three of eight patients
with in vivo diagnosis died of post-surgical complications
(x2, P = 0.03). It should also be noted that the duration of the
period between symptom onset and diagnosis was three times
shorter in patients treated with chemotherapy compared with
the rest. This could be explained either by more rapidly pro-
gressive disease or, more probably, by diagnostic delay. Since
IVL is an aggressive and disseminated disease, diagnostic
delay is usually associated with rapid and progressive impair-
ment of multiorgan function and PS, which hampers the use
of adequate chemotherapy. Furthermore, in our series, there
was a significantly different distribution of sites of disease
between subgroups of patients divided according to the use of
chemotherapy. Importantly, cutaneous lesions were signifi-
cantly more common in patients treated with chemotherapy
with respect to the rest. As suggested by multivariate analysis,
cutaneous presentation is independently associated with better
survival and allows a more rapid histological diagnosis when
considering its earlier detection and easier access. On the
other hand, CNS involvement, which is associated with worse
prognosis, was significantly more common in patients who did
not receive chemotherapy. Intriguingly, fever, anemia and a
raised ESR were significantly more common in the group of
patients treated with chemotherapy. Even if these observations
remain unexplained, it could be hypothesized that, in some
cases, these features may have lead to the performance of a
bone marrow biopsy, which allowed an earlier histopatho-
logical diagnosis and timely treatment.
Response assessment after initial chemotherapy can be trou-
blesome in IVL patients because measurable disease (i.e. lym-
phadenopathy and tumor masses) is often lacking. In the
present series, patients treated with chemotherapy had measur-
able cutaneous lesions in 12 cases, hepatosplenic nodules in
two, bone marrow infiltration in two, CNS lesions in two, pul-
monary nodules in one and lymphadenopathy in one. In two
patients, no measurable disease remained after surgical biopsy;
one of them died of toxicity during chemotherapy, the other
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one experienced early normalization of laboratory parameters
and symptomatic improvement. In the latter case, complete
remission has been confirmed by the fact that the patient is
relapse-free at 71 months from diagnosis. Additional evidence
is needed to confirm whether B symptoms and laboratory
parameters are useful tools in defining objective responses in
IVL cases without measurable disease.
In conclusion, clinical benefit of anthracycline-based che-
motherapy is conditioned by selection in IVL patients. Lethal
complications and diagnostic delay, resulting from variable
clinical presentation and rapidly progressive disease, are the
most important causes of patient selection. Notwithstanding,
anthracycline-based chemotherapy remains the cornerstone of
IVL treatment, producing a moderate rate of durable remis-
sions, mostly in patients with disease limited to the skin, good
PS and small tumor burden. Early consolidation with high-dose
chemotherapy and ASCT should be considered in patients
<60 years of age with unfavorable features. For patients with
CNS involvement, the CHOP regimen is a sub-optimal treat-
ment and it seems likely that drugs used in other aggressive pri-
mary CNS lymphomas, such as methotrexate and cytarabine,
should be included. The role of rituximab, an effective anti-
CD20 monoclonal antibody against B-cell lymphomas, should
also be investigated in IVL patients. Management of patients
with the ‘cutaneous form’ of IVL remains a matter of debate
considering that some cases show excellent prognosis even if
treated without chemotherapy, while others experience early
relapse after intensive therapy. Biological studies could help us
to distinguish different risk groups in patients with the
‘cutaneous form’ of IVL, which need distinct therapeutic
approaches.
In brief, survival of IVL patients is still disappointing and
further efforts to improve our knowledge of this malignancy
are needed; they will result in a higher proportion of early
diagnoses and better control of complications, with consequent
delivery of adequate and timely treatment.
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